Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Cvac trial in resected stage I-II pancreatic adenocarcinoma
2014-000676-26Phase 2Terminated
- Sponsor
- Immutep Limited
- Start
- May 2014
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CVac in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Immutep Limited. Primary endpoint: Safety and Tolerability. Started May 2014; status: terminated.
02
Drugs
CVac
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-000676-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000676-26.